MFN2 and Charcot-Marie-Tooth disease type 2A1: Our study utilized a comprehensive mitochondrial drug screening and evaluation platform to assess S89's efficacy across multiple model systems, including Mfn2 KO MEFs, cultured CMT2A mouse neurons and CMT2A patient-derived motor neurons.